CompletedPhase 1

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

United States139 participantsStarted 2013-01-01

Plain-language summary

This study aims to assess postoperative blood loss and transfusion rates in total hip replacement after one-time administration of topical tranexamic acid.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All adult patients over age eighteen * Primary unilateral total hip arthroplasty at Henry Ford Hospital (Detroit, Michigan, United States) and Henry Ford West Bloomfield Hospital (West Bloomfield, Michigan, United States) Exclusion Criteria: * patient history of venous thromboembolic disease or coagulopathy * use of anticoagulant medications within 7 days of surgery * history of arterial embolic disease * history of Class III or IV heart failure * renal failure * intraoperative cardiovascular, pulmonary, orthopaedic, or anesthetic complication (MI, intraoperative fracture, vasopressor support, emergent intubation).

What they're measuring

postoperative blood loss

Timeframe: participants will be followed for the duration of hospital stay, an expected average of 3 days

Trial details

NCT IDNCT01683955

SponsorHenry Ford Health System

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-11-03

View on ClinicalTrials.gov More Acute Blood Loss Anemia trials